Bonnie Ky, MD, MSCE
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine
Graduate Group Affiliations
Contact information
Hospital of the University of Pennsylvania
11-105 Smilow Center for Translational Research
3400 Civic Center Boulevard
Philadelphia, PA 19104
11-105 Smilow Center for Translational Research
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-573-6606
Fax: 215-746-7415
Fax: 215-746-7415
Email:
bonnie.ky@uphs.upenn.edu
bonnie.ky@uphs.upenn.edu
Publications
Education:
BS (Chemical Engineering )
Massachusetts Institute of Technology, 1995.
MD (Medicine)
University of Pennsylvania, 2001.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2009.
Permanent linkBS (Chemical Engineering )
Massachusetts Institute of Technology, 1995.
MD (Medicine)
University of Pennsylvania, 2001.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2009.
Description of CVI Expertise
My research interests are in translational cardiovascular epidemiology with a focus on the study of novel signaling pathways and mechanisms in human heart failure, cardiac remodeling, and chemotherapy cardiotoxicity. Current projects include:1) Neuregulin Signaling:
We are interested in defining the relevance of circulating neuregulin as it relates to human heart failure and cardiac remodeling. I am the principal investigator of a longitudinal study determining the association between circulating neuregulin levels and cardiac remodeling and clinical outcomes in the Penn Heart Failure Study and the Chronic Renal Insufficiency Cohort.
We are also engaged in a study of genetic variations in the neuregulin/ErbB signaling pathway and how they relate to circulating levels, cardiac remodeling, and clinical outcomes in these and other community-based cohorts. We are actively collaborating on a therapeutics trial of neuregulin in systolic heart failure.
2) Chemotherapy Cardiotoxicity:
We are interested in defining novel circulating biomarker, genetic variations, and sensitive echocardiographic indices predictive of chemotherapy cardiotoxicity. Our objective is to gain mechanistic and translational insight into the potential dsyregulation of various pathway-based markers in the pathophysiology of this disease.
Selected Publications
Christian JB, Finkle JK, Ky B, Douglas PS, Gutstein DE, Hockings PD, Lainee P, Lenihan DJ, Mason JW, Sager PT, Todaro TG, Hicks KA, Ko H, Lindenfeld J, Michelson EL, Milligan J, Munley JY, Taichlen JS, Shahlaee A, Strnadova C, Ye B, Turner JR: Cardiac Imaging Approaches to Evaluate Drug-Induced Myocardial Dysfunction. American Heart Journal 164(6): 846-55, December 2012.Sawaya H, Sebag I, Plana JC, Januzzi JL, Ky B, Tan TC, Cohen V, Banchs J, Carver J, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M: Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated with Anthracyclines, Taxanes, and Trastuzumab. Circulation Cardiovascular Imaging 5(5): 596-603, September 2012.
French B, Saha-Chaudhuri P, Ky B, Cappola TP, Heagerty PJ: Development and Evaluation of Multi-Marker Risk Scores for Clinical Prognosis. Statistical Methods in Medical Research July 2012 Notes: Epub ahead of print.
Ky B, Plappert T, Kirkpatrick J, Silvestry FE, Ferrari VA, Keane MG, Wiegers SE, Chirinos JA, St John Sutton M: Left Ventricular Remodeling in Human Heart Failure: Quantitative Echocardiographic Assessment of 1,794 Patients. Echocardiography 29(7): 758-65, April 2012.
Ky B, French B, Levy WC, Sweitzer NK, Fang JC, Wu AHB, Goldberg LR, Jessup M, Cappola TP: Multiple Biomarkers for Risk Prediction in Chronic Heart Failure. Circulation. Heart Failure 5(2): 183-90, March 2012.
Flory JH, Ky B, Haynes K, M Brunelli S, Munson J, Rowan C, Strom BL, Hennessy S: Observational Cohort Study of the Safety of Digoxin Use in Women with Heart Failure. BMJ open 2(2): e000888, 2012.
Ogbara J, Logani S, Ky B, Chirinos JA, Silvestry FE, Eberman K, Moss JD, Ferrari VA, Keane MG, St John Sutton M, Wiegers SE, Kirkpatrick JN: The Utility of Prescreening Transesophageal Echocardiograms: a Prospective Study. Echocardiography 28(7): 767-73, August 2011.
Ky B, French B, Ruparel K, Sweitzer NK, Fang JC, Levy WC, Sawyer DB, Cappola TP: The Vascular Marker Soluble FMS-like Tyrosine Kinase 1 Is Associated with Disease Severity and Adverse Outcomes in Chronic Heart Failure. Journal of the American College of Cardiology 58(4): 386-94, July 2011.
Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, Gosavi S, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M: Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients. The American Journal of Cardiology 107(9): 1375-80, May 2011.
Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, Dries DL, Tang WHW, Wu AHB, Fang JC, Boxer R, Sweitzer NK, Levy WC, Goldberg LR, Jessup M, Cappola TP: High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure. Circulation. Heart Failure 4(2): 180-7, March 2011.